The market expects Gritstone bio Inc. (GRTS) to deliver flat earnings compared to the year-ago quarter on higher revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand ...

EMERYVILLE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced the appointment of Stephen Webster to its Board of Directors. A veteran finance executive in the biotechnology industry, Mr. Webster has served as an executive for several renowned companies and held key roles in raising capital, business development transactions and operations for over 30 years. The company also ...

-- Paper details vaccine design optimization process of Gritstone's "off-the-shelf" or shared neoantigen vaccine platform, SLATE -- -- Discovery of a novel immunodominance hierarchy of tumor neoantigens (including KRAS) enabled the development of a more potent, KRAS-specific vaccine candidate (SLATE-KRAS) being studied by Steven A. Rosenberg of the National Cancer Institute (NCI) -- -- Publication underscores the important role of antigen selection and cassette design in the development of neoantigen-direct ...

Gritstone bio Inc. (GRTS) has been beaten down lately with too much selling pressure. While the stock has lost 63.4% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator ...

-- State-of-the-art neoantigen prediction platform (EDGE™) now predicts HLA Class I presentation of epitopes with >80% accuracy -- -- Newly developed EDGE-II model achieves superior predictive performance of HLA Class II presentation and CD4+ immunogenicity over publicly available models -- -- Combined with Gritstone's vaccine vectors, EDGE has demonstrated best-in-class potential in identifying neoantigens capable of eliciting T cell immune responses for robust and durable immunity -- EMERYVILLE, Calif., A ...

red_moon_rise In my previous Gritstone bio (NASDAQ:GRTS) article, I discussed how the company’s technology could make it a cutting-edge infectious disease firm with a strong list of collaborations that could rival Moderna (MRNA) and BioNTech (BNTX). However, I also noted that the company's biggest upside potential was its oncology programs, notably GRANITE, which could transform cancer treatment by targeting neoantigens, with encouraging early-stage results. Despite the upside potential, I also pointed ...

Gritstone Bio (GRTS) is a clinical-stage biotechnology company focused on developing vaccines targeting multiple indications, including cancer.In the past week, the company’s stock lost 57.5%. This downside came after management came out with preliminary results from the mid-stage portion of the phase II/III study on its investigational personalized cancer vaccine (PCV), Granite.The phase II/III study evaluated the combination of Granite as a maintenance therapy in patients with metastatic microsatellite st ...

Gritstone Bio (NASDAQ:GRTS) stock is falling on Tuesday after the clinical-stage biotechnology company announced the pricing of an underwritten public offering for its shares.This public offering has the company selling 8,333,333 shares of GRTS stock for $1.50 each. These shares also come with warrants to purchase another 8,333,333 shares of GRTS stock. The exercise price for the warrants is $1.65 per share.In addition to this, certain investors are allowed to purchase pre-funded warrants instead of GRTS st ...

EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced the pricing of an approximately $32.5 million underwritten public offering of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying common warrants to purchase common stock (or pre-funded warrants to purchase common stock in lieu thereof), before deducting underwritin ...

Exhibit 99.1 Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates -- Preliminary data from Phase 2 portion of Phase 2/3 study evaluating GRANITE, Gritstone's personalized cancer vaccine in front-line metastatic, microsatellite-stable colorectal cancer (MSS-CRC) remain expected in 1Q 2024 -- -- National Cancer Institute-led Phase 1 study evaluating Gritstone's "off-the-shelf" cancer vaccine, SLATE, combined with neoantigen cell therapy expected to begin in ...